Aerius

Nchi: Umoja wa Ulaya

Lugha: Kiingereza

Chanzo: EMA (European Medicines Agency)

Nunua Sasa

Taarifa za kipeperushi Taarifa za kipeperushi (PIL)
02-08-2023
Tabia za bidhaa Tabia za bidhaa (SPC)
02-08-2023

Viambatanisho vya kazi:

desloratadine

Inapatikana kutoka:

N.V. Organon

ATC kanuni:

R06AX27

INN (Jina la Kimataifa):

desloratadine

Kundi la matibabu:

Antihistamines for systemic use,

Eneo la matibabu:

Rhinitis, Allergic, Perennial; Urticaria; Rhinitis, Allergic, Seasonal

Matibabu dalili:

Aerius is indicated for the relief of symptoms associated with:allergic rhinitis;urticaria.

Bidhaa muhtasari:

Revision: 50

Idhini hali ya:

Authorised

Idhini ya tarehe:

2001-01-15

Taarifa za kipeperushi

                                30
B. PACKAGE LEAFLET
31
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT
AERIUS 5 MG FILM-COATED TABLETS
desloratadine
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor, pharmacist or
nurse.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor, pharmacist or nurse.
This includes any possible
side effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Aerius is and what it is used for
2.
What you need to know before you take Aerius
3.
How to take Aerius
4.
Possible side effects
5.
How to store Aerius
6.
Contents of the pack and other information
1.
WHAT AERIUS IS AND WHAT IT IS USED FOR
WHAT AERIUS IS
Aerius contains desloratadine which is an antihistamine.
HOW AERIUS WORKS
Aerius is an antiallergy medicine that does not make you drowsy. It
helps control your allergic
reaction and its symptoms.
WHEN AERIUS SHOULD BE USED
Aerius relieves symptoms associated with allergic rhinitis
(inflammation of the nasal passages caused
by an allergy, for example, hay fever or allergy to dust mites) in
adults and adolescents 12 years of age
and older. These symptoms include sneezing, runny or itchy nose, itchy
palate, and itchy, red or
watery eyes.
Aerius is also used to relieve the symptoms associated with urticaria
(a skin condition caused by an
allergy). These symptoms include itching and hives.
Relief of these symptoms lasts a full day and helps you to resume your
normal daily activities and
sleep.
2.
WHAT YOU NEED TO KNOW BEFORE YOU TAKE AERIUS
DO NOT TAKE AERIUS
-
if you are allergic to desloratadine, or any of the other ingredients
of this medicine (listed in
section 6) or to loratadine.
WARNINGS AND PRECAUTIONS
Talk to your doctor, pharmacist or nurse before taking Aerius:
-

                                
                                Soma hati kamili
                                
                            

Tabia za bidhaa

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Aerius 5 mg film-coated tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains 5 mg desloratadine.
Excipient(s) with known effect
This medicinal product contains lactose (see section 4.4).
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Film-coated tablets
Light blue, round and embossed film-coated tablets with elongated
letters “S” and “P” on one side and
plain on the other. The diameter of the film-coated tablet is 6.5 mm.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Aerius is indicated in adults and adolescents aged 12 years and older
for the relief of symptoms
associated with:
-
allergic rhinitis (see section 5.1)
-
urticaria (see section 5.1)
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Posology
_Adults and adolescents (12 years of age and over) _
The recommended dose of Aerius is one tablet once a day.
Intermittent allergic rhinitis (presence of symptoms for less than 4
days per week or for less than
4 weeks) should be managed in accordance with the evaluation of
patient’s disease history and the
treatment could be discontinued after symptoms are resolved and
reinitiated upon their reappearance.
In persistent allergic rhinitis (presence of symptoms for 4 days or
more per week and for more than
4 weeks), continued treatment may be proposed to the patients during
the allergen exposure periods.
_ _
_Paediatric population _
There is limited clinical trial efficacy experience with the use of
desloratadine in adolescents
12 through 17 years of age (see sections 4.8 and 5.1).
The safety and efficacy of Aerius 5 mg film-coated tablets in children
below the age of 12 years have
not been established.
Method of administration
Oral use.
The dose can be taken with or without food.
3
4.3
CONTRAINDICATIONS
Hypersensitivity to the active substance, to any of the excipients
listed in section 6.1, or to loratadine.
4.4
SPECIAL WARNINGS AND PRECAUTIONS FOR USE
Renal function impairment
In th
                                
                                Soma hati kamili
                                
                            

Nyaraka katika lugha zingine

Taarifa za kipeperushi Taarifa za kipeperushi Kibulgaria 02-08-2023
Tabia za bidhaa Tabia za bidhaa Kibulgaria 02-08-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kibulgaria 09-06-2015
Taarifa za kipeperushi Taarifa za kipeperushi Kihispania 02-08-2023
Tabia za bidhaa Tabia za bidhaa Kihispania 02-08-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kihispania 09-06-2015
Taarifa za kipeperushi Taarifa za kipeperushi Kicheki 02-08-2023
Tabia za bidhaa Tabia za bidhaa Kicheki 02-08-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kicheki 09-06-2015
Taarifa za kipeperushi Taarifa za kipeperushi Kidenmaki 02-08-2023
Tabia za bidhaa Tabia za bidhaa Kidenmaki 02-08-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kidenmaki 09-06-2015
Taarifa za kipeperushi Taarifa za kipeperushi Kijerumani 02-08-2023
Tabia za bidhaa Tabia za bidhaa Kijerumani 02-08-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kijerumani 09-06-2015
Taarifa za kipeperushi Taarifa za kipeperushi Kiestonia 02-08-2023
Tabia za bidhaa Tabia za bidhaa Kiestonia 02-08-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiestonia 09-06-2015
Taarifa za kipeperushi Taarifa za kipeperushi Kigiriki 02-08-2023
Tabia za bidhaa Tabia za bidhaa Kigiriki 02-08-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kigiriki 09-06-2015
Taarifa za kipeperushi Taarifa za kipeperushi Kifaransa 02-08-2023
Tabia za bidhaa Tabia za bidhaa Kifaransa 02-08-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kifaransa 09-06-2015
Taarifa za kipeperushi Taarifa za kipeperushi Kiitaliano 02-08-2023
Tabia za bidhaa Tabia za bidhaa Kiitaliano 02-08-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiitaliano 09-06-2015
Taarifa za kipeperushi Taarifa za kipeperushi Kilatvia 02-08-2023
Tabia za bidhaa Tabia za bidhaa Kilatvia 02-08-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kilatvia 09-06-2015
Taarifa za kipeperushi Taarifa za kipeperushi Kilithuania 02-08-2023
Tabia za bidhaa Tabia za bidhaa Kilithuania 02-08-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kilithuania 09-06-2015
Taarifa za kipeperushi Taarifa za kipeperushi Kihungari 02-08-2023
Tabia za bidhaa Tabia za bidhaa Kihungari 02-08-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kihungari 09-06-2015
Taarifa za kipeperushi Taarifa za kipeperushi Kimalta 02-08-2023
Tabia za bidhaa Tabia za bidhaa Kimalta 02-08-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kimalta 09-06-2015
Taarifa za kipeperushi Taarifa za kipeperushi Kiholanzi 02-08-2023
Tabia za bidhaa Tabia za bidhaa Kiholanzi 02-08-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiholanzi 09-06-2015
Taarifa za kipeperushi Taarifa za kipeperushi Kipolandi 02-08-2023
Tabia za bidhaa Tabia za bidhaa Kipolandi 02-08-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kipolandi 09-06-2015
Taarifa za kipeperushi Taarifa za kipeperushi Kireno 02-08-2023
Tabia za bidhaa Tabia za bidhaa Kireno 02-08-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kireno 09-06-2015
Taarifa za kipeperushi Taarifa za kipeperushi Kiromania 02-08-2023
Tabia za bidhaa Tabia za bidhaa Kiromania 02-08-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiromania 09-06-2015
Taarifa za kipeperushi Taarifa za kipeperushi Kislovakia 02-08-2023
Tabia za bidhaa Tabia za bidhaa Kislovakia 02-08-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kislovakia 09-06-2015
Taarifa za kipeperushi Taarifa za kipeperushi Kislovenia 02-08-2023
Tabia za bidhaa Tabia za bidhaa Kislovenia 02-08-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kislovenia 09-06-2015
Taarifa za kipeperushi Taarifa za kipeperushi Kifinlandi 02-08-2023
Tabia za bidhaa Tabia za bidhaa Kifinlandi 02-08-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kifinlandi 09-06-2015
Taarifa za kipeperushi Taarifa za kipeperushi Kiswidi 02-08-2023
Tabia za bidhaa Tabia za bidhaa Kiswidi 02-08-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiswidi 09-06-2015
Taarifa za kipeperushi Taarifa za kipeperushi Kinorwe 02-08-2023
Tabia za bidhaa Tabia za bidhaa Kinorwe 02-08-2023
Taarifa za kipeperushi Taarifa za kipeperushi Kiaisilandi 02-08-2023
Tabia za bidhaa Tabia za bidhaa Kiaisilandi 02-08-2023
Taarifa za kipeperushi Taarifa za kipeperushi Kroeshia 02-08-2023
Tabia za bidhaa Tabia za bidhaa Kroeshia 02-08-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kroeshia 09-06-2015

Tafuta arifu zinazohusiana na bidhaa hii

Tazama historia ya hati